The Canadian Agency for Drugs and Technologies in Health, the Canadian entity responsible for health technology assessments, has announced that it has revised its approach to reviewing biosimilars.
The Canadian Agency for Drugs and Technologies in Health (CADTH), the Canadian entity responsible for health technology assessments, has announced that it has revised its approach to reviewing biosimilars. CADTH says that its new process will provide for shorter timelines, fewer submission requirements, and an abbreviated biosimilar summary dossier template for manufacturers’ use.
CADTH reports that its experience in reviewing biosimilars, together with stakeholder input gathered through an open consultation in 2017—which garnered input from 25 individuals and organizations—allowed the organization to identify key areas for improvement in its internal processes.
The new procedure will reduce the number of submission requirements that manufacturers must meet when submitting a biosimilar summary dossier (a document in which manufacturers provide all relevant information for a biosimilar product for the pan-Canadian Pharmaceutical Alliance and participating Canadian jurisdictions to make decision about which products to include in their drug plans). The dossier is intended to give CADTH the information it needs to assess the cost of biosimilars, consolidate stakeholder feedback, and identify potential implementation issues.
In the biosimilar dossier, manufacturers must submit drug pricing information for the smallest dispensable unit of the biosimilar—for all packaging formats—and must not be exceeded for any of the drug plans that choose to adopt the biosimilar after the review process has been completed. The price for the drug must be reported for 4 decimal places, and will be disclosed in all CADTH reports. The price submitted is used in the pharmacoeconomic evaluation of the biosimilar, and in budget impact analyses for the models used in individual Canadian provinces’ health plans.
The department may also choose to review evidence from switching studies from the reference biologic to the biosimilar on a case-by-case basis, and says that “This determination is made in consultation with the participating public drug plans and may be influenced by the volume and quality of available evidence, as well as reimbursement and switching policies for other biosimilars for the same reference drug and/or indications.” CADTH will also collect and summarize input from patient groups, and will share that input with drug plans.
After reviewing all of the submitted information, CADTH’s reviewers will provide summary of stakeholder input comment on the manufacturer’s cost information, and forward its summary dossier to both the applicant and participating drug plans for a determination. CADTH’s biosimilar summary dossiers will also be available publicly and without redaction.
CADTH’s new submission process took effect on February 13, and is expected to reduce the overall biosimilar review timeline from 6 months to 3 months.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.